Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in patients receiving chronic hemodialysis. This was a multicenter, randomized, open-label, phase 3 study of adults receiving hemodialysis with an...

Full description

Bibliographic Details
Main Authors: Matthias Girndt, Manfred Plüer, Frank Dellanna, Ann K. Michelsen, Joachim Beige, Kai Toussaint, Hubert J. Wehweck, Michael Koch, Syrus Hafezi Rachti, Justus Faust, Hans-Peter Bosselmann, Oliver Witzke, Robert S. Janssen, the HBV-18 Study Investigators
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cpg 1018 adjuvant
hepatitis b virus
vaccine
hemodialysis
immunogenicity
safety
Online Access:http://dx.doi.org/10.1080/21645515.2022.2136912

Internet

http://dx.doi.org/10.1080/21645515.2022.2136912

Similar Items